Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Etakafusp alfa - Asher Biotherapeutics

Next Previous
Drug Profile

Etakafusp alfa - Asher Biotherapeutics

Alternative Names: AB-248

Latest Information Update: 11 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Asher Biotherapeutics
  • Class Anti-infectives; Antineoplastics; Immunotherapies; Interleukins; Recombinant fusion proteins
  • Mechanism of Action CD8 positive T lymphocyte stimulants; Interleukin 2 replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 23 May 2025 AstraZeneca plans the phase I/II ALTAIR trial in Non-small Cell Lung Cancer (Late-stage disease, Metastatic disease) in Belgium, Brazil, China, France, Georgia, South Korea, Malaysia, Moldova, Netherlands, Peru, Poland, Serbia, Spain, Taiwan, Thailand, Turkey and the US (IV) (NCT06996782)
  • 08 Jan 2025 Efficacy and adverse events data from a phase Ia/Ib trial in Solid tumours released by Asher Biotherapeutics
  • 08 Jan 2025 Amgen plans a phase Ib trial for Small cell lung cancer (Late-stage disease, Combination therapy)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top